Director – Sales

TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimenSupported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA® in all pooled endoscopic endpoints within a double-blinded registrational trialTREMFYA® approval in Crohn's disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for this dual-acting IL-23i in the U.S.HORSHAM, Pa., March 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.1 This milestone builds upon the FDA approval of TREMFYA® in moderately to severely active ulcerative colitis (UC), one of two main forms of inflammatory bowel disease (IBD),2 which impacts the lives of nearly three million Americans.3 TREMFYA® is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including CD.4,5,6,7,8"Despite the progress in the management of Crohn's disease, many patients experience debilitating symptoms and are in need of new treatment options," said Remo Panaccione, MD, FRCPC, Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary and lead investigator of the Phase 3 GRAVITI study. "The approval of TREMFYA offers an IL-23 inhibitor that has shown robust rates of endoscopic remission with both subcutaneous and intravenous induction regimens. Importantly, the fully subcutaneous regimen offers choice and flexibility for patients and providers that have not been available before."This approval is supported by results from multiple rigorous Phase 3 trials evaluating more than 1,300 patients with moderately to severely active CD who failed or were intolerant to conventional therapy (i.e. corticosteroids or immunomodulators) or biologics.6 The GRAVITI study evaluated TREMFYA® SC induction and maintenance therapy versus placebo

NEW YORK, March 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against TFI International Inc. ("TFI" or "the Company") (NYSE: TFII) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired TFI securities between April 26, 2024 and February 19, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/TFII.Case DetailsThe Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material facts regarding TFI's business, operations, and prospects, including allegations that: (1) TFI was losing small and medium business customers; (2) as a result, the Company's TForce revenue was declining; (3) TFI was experiencing difficulties managing its costs; and (4) as a result of the foregoing, the profitability of its largest business segment was declining.What's Next?A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/TFII. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660

BETHESDA, Md., March 20, 2025 /PRNewswire/ -- AGNC Investment Corp. (Nasdaq: AGNC) ("AGNC" or the "Company") announced today that, effective March 20, 2025, Peter Federico, the Company's President and Chief Executive Officer, will also serve as AGNC's Chief Investment Officer. Christopher Kuehl, the Company's current Chief Investment Officer, will assume the newly created role of Head of Investment Research and Strategy. In his new capacity, Mr. Kuehl will remain an integral member of AGNC's management team and provide a dedicated focus on incorporating enhanced data and analytical capabilities into the Company's portfolio management strategies."Our goal of generating attractive yield-driven total returns for our stockholders requires AGNC to continuously evolve in today's dynamic and everchanging macroeconomic environment," said Mr. Federico